Back to top

Analyst Blog

Anacor Pharmaceuticals, Inc. (ANAC - Snapshot Report) reported second quarter 2013 net loss per share of 32 cents, narrower than the Zacks Consensus Estimate of a loss of 38 cents and the year-ago loss of 47 cents per share.

Second quarter revenues were $3.4 million, compared with $2.6 million in the year-ago quarter. Revenues beat the Zacks Consensus Estimate of $3 million.

Research and development expenses fell 28% year over year to $10.1 million. The decline was due to lower clinical expenses for tavaborole and preclinical studies for AN2728.

Selling, general and administrative expenses increased 90.4% year over year to $5.1 million, primarily driven by higher legal fees related to disputes with Valeant Pharmaceuticals International, Inc. (VRX - Snapshot Report).

Pipeline Update

In Jul 2013, Anacor submitted a New Drug Application (NDA) for tavaborole to the U.S. Food and Drug Administration (FDA) for the prevention of onychomycosis. An arbitration hearing is scheduled for Sep 2013 to resolve the breach of contract dispute between Anacor and Valeant.

In Jul 2013, Anacor commenced the MUSE (maximal use systemic exposure) study in children to evaluate the effects of its atopic dermatitis candidate, AN2728. Anacor intends to start a TQT (thorough QT) study in the third quarter of 2013. Results from both studies are expected this year. For AN2728, a phase III study in atopic dermatitis will start in the fourth quarter of 2013 or first quarter of 2014, depending on the completion of the MUSE study.

In Apr 2013, Anacor inked a deal with the Bill & Melinda Gates Foundation for the discovery of drug candidates for the treatment of two filarial worm diseases (onchocerciasis - river blindness and lymphatic filariasis - elephantiasis) and tuberculosis. Anacor will also create an expanded library of boron compounds, which will screen additional potential drug candidates for the treatment of neglected diseases. The Gates Foundation will have access to this expanded library.

Anacor carries a Zacks Rank #3 (Hold). Currently, companies like Pharmacyclics, Inc. (PCYC - Analyst Report) and Actelion Ltd. (ALIOF) look well-positioned with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SYNAPTICS I… SYNA 78.11 +8.14%
CENTURY ALU… CENX 19.88 +5.74%
GREEN PLAIN… GPRE 39.41 +5.12%
PILGRIM'S P… PPC 28.82 +3.08%
THE PANTRY… PTRY 18.41 +2.79%